Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 195

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 195
---
3 Plan. Subject to adjustment as provided in the 2023 Plan, the maximum aggregate
number of shares that may be issued under the 2023 Plan will be cumulatively increased on January 1, 2024 and on each subsequent January
1, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately
preceding December 31, or (ii) an amount determined by the Board.

Additionally, if any award issued pursuant to
the 2023 Plan expires or becomes exercisable without having been exercised in full, is surrendered pursuant to an exchange program, as
provided in the 2023 Plan, or, with respect to restricted stock, restricted stock units (“RSUs”), performance units or performance
shares, is forfeited to or repurchased by the Company due to the failure to vest, the unpurchased shares (or for awards other than stock
options or stock appreciation rights the forfeited or repurchased shares) which were subject thereto will become available for future
grant or sale under the 2023 Plan (unless the 2023 Plan has terminated). With respect to stock appreciation rights, only shares actually
issued pursuant to a stock appreciation right will cease to be available under the 2023 Plan; all remaining shares under stock appreciation
rights will remain available for future grant or sale under the 2023 Plan (unless the 2023 Plan has terminated). Shares that have actually
been issued under the 2023 Plan under any award will not be returned to the 2023 Plan and will not become available for future distribution
under the 2023 Plan; provided, however, that if shares issued pursuant to awards of restricted stock, restricted stock units, performance
shares or performance units are repurchased by the Company or are forfeited to the Company due to the failure to vest, such shares will
become available for future grant under the 2023 Plan. Shares used to pay the exercise price of an award or to satisfy the tax withholdings
related to an award will become available for future grant or sale under the 2023 Plan. To the extent an award under the 2023 Plan is
paid out in cash rather than shares, such cash payment will not result in reducing the number of shares available for issuance under the
2023 Plan.

Notwithstanding the foregoing and, subject to
adjustment as provided in the 2023 Plan, the maximum number of shares that